Committee for Veterinary Medicinal Products: 49th meeting

11 November 1999

Under the Chairmanship of Professor R. Kroker the forty-ninth meeting of the Committee for Veterinary Medicinal Products took place in London on 9 - 11 November 1999.

CVMP opinions

• The Committee adopted a unanimous positive opinion and CVMP assessment report for a vaccine falling under Part A of the Annex to Council Regulation (EEC) No. 2309/93 and indicated for infectious bovine rhinotracheitis in cattle.
• The Committee also adopted unanimous positive opinions and CVMP assessment reports for two extensions to a product authorised under the centralised procedure under Part B of the Annex to Council Regulation (EEC) No. 2309/93 and indicated for the alleviation of inflammation and pain in musculo-skeletal disorders in dogs.
• The Committee adopted an opinion and assessment report for a type I variation for Fevaxyn Pentofel.
• The Committee adopted an opinion for an extension of maximum residue limits (MRLs) for an existing substance to a further tissue and to a further target species.
• The Committee considered appeals in respect of MRL opinions for 2 substances, neither of which was successful.

Availability of medicines

The Committee adopted a recommendation to include thiopental sodium in Annex II of Council Regulation (EEC) No 2377/90; this substance having been identified previously as essential (see CVMP position papers on availability of veterinary medicines EMEA/CVMP 151/99-FINAL and EMEA/CVMP/731/99) and for which further data in the public domain had become available.

The next meeting of the CVMP will be held on 7 –9 December 1999.

Committee for Veterinary Medicinal Products: 49th meeting

Reference Number: EMEA/CVMP/778/99